Logotype for BASF SE

BASF (BAS) Q4 2025 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for BASF SE

Q4 2025 earnings summary

27 Feb, 2026

Executive summary

  • Achieved major milestones in the Winning Ways strategy, including the startup of the Zhanjiang Verbund site, accelerated cost savings, and significant organizational streamlining.

  • Faced a volatile and challenging global market in 2025, with strong headwinds for the chemical industry and a focus on controllable factors.

  • FY 2025 saw higher volumes but was impacted by negative currency effects and lower prices, leading to a 2.9% decline in sales year-over-year.

  • EBITDA before special items fell 9.5% to €6,554m, mainly due to upstream margin pressure and currency headwinds.

  • Net income rose to €1.6 billion, supported by portfolio gains and special income from reimbursements related to expropriated Russian assets.

Financial highlights

  • Sales declined considerably year-over-year in Q4 2025 due to currency headwinds and lower prices, despite slightly higher volumes in most segments.

  • EBITDA before special items was €1.03 billion in Q4 (down 27.9%), and €6.6 billion for the full year (down from 2024), mainly due to lower margins and negative currency effects.

  • Net income improved by 25% to €1.6 billion, with net income from shareholdings rising to €1.3 billion, driven by Wintershall Dea and special income.

  • Free cash flow increased to €1.3 billion, aided by reduced capex.

  • Net debt reduced to €18.3 billion by year-end; equity ratio stable at 45.1%.

Outlook and guidance

  • 2026 guidance: EBITDA before special items expected between €6.2–7.0 billion; free cash flow between €1.5–2.3 billion.

  • No meaningful market upswing or easing of geopolitical tensions expected in the near term; gradual recovery anticipated in late 2026 and 2027.

  • CapEx planned at €3.3–3.4 billion in 2026, with a four-year plan of €13 billion (20% lower than previous forecast).

  • Dividend proposal of €2.25 per share (5.1% yield), with at least €12 billion to be distributed to shareholders via dividends and buybacks by 2028.

  • Segment outlook: Chemicals and Nutrition & Care to see considerable EBITDA increases; Materials, Surface Technologies, and Agricultural Solutions to decline.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more